Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Gauthier

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Bone Marrow Transplantation|April 20, 2020
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overviewMohamad Mohty, Remy Dulery, Jordan Gauthier, et al.
Transplantation and Cellular Therapy|August 23, 2024
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 TherapeuticsEmily A Rosen, Elizabeth M Krantz, Denise J McCulloch, et al.
Haematologica|June 1, 2023
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L Crombie, Caron A Jacobson, Robert Redd, et al.
European Journal of Haematology|May 2, 2018
Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioningMarie Robin, Kavita Raj, Sylvie Chevret, et al.
Bulletin Du Cancer|November 28, 2017
[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Ibrahim Yakoub-Agha, Christophe Ferrand, Yves Chalandon, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Novel M-component based biomarkers in Waldenström's macroglobulinemiaXavier Leleu, Efstathios Koulieris, Dimitrios Maltezas, et al.
Blood Advances|April 9, 2025
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapyEleftheria Kampouri, Patrick Flaherty, Hu Xie, et al.
Transplantation|March 14, 2015
Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Gandhi Damaj, Carole Langlois, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Bone Marrow Transplantation|April 20, 2020
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overviewMohamad Mohty, Remy Dulery, Jordan Gauthier, et al.
Transplantation and Cellular Therapy|August 23, 2024
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 TherapeuticsEmily A Rosen, Elizabeth M Krantz, Denise J McCulloch, et al.
Haematologica|June 1, 2023
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L Crombie, Caron A Jacobson, Robert Redd, et al.
European Journal of Haematology|May 2, 2018
Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioningMarie Robin, Kavita Raj, Sylvie Chevret, et al.
Bulletin Du Cancer|November 28, 2017
[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Ibrahim Yakoub-Agha, Christophe Ferrand, Yves Chalandon, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Novel M-component based biomarkers in Waldenström's macroglobulinemiaXavier Leleu, Efstathios Koulieris, Dimitrios Maltezas, et al.
Blood Advances|April 9, 2025
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapyEleftheria Kampouri, Patrick Flaherty, Hu Xie, et al.
Transplantation|March 14, 2015
Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular TherapyJordan Gauthier, Gandhi Damaj, Carole Langlois, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Pageof 9